Biodexa Pharmaceuticals PLC
NASDAQ:BDRX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Biodexa Pharmaceuticals PLC
NASDAQ:BDRX
|
UK |
Intrinsic Value
The intrinsic value of Biodexa Pharmaceuticals PLC (BDRX) under the Base Case is 5.5666 USD per share.
Compared with the current market price of 0.4314 USD, the stock appears
Undervalued by 92% .
The intrinsic value is the average of valuations using the DCF method and multiples.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What Biodexa Pharmaceuticals Does
Biodexa Pharmaceuticals Plc is a drug delivery technology company. The company is headquartered in Abingdon, Oxfordshire and currently employs 11 full-time employees. The company went IPO on 2014-12-08. The firm is developing a pipeline of products for the treatment of diseases with unmet medical needs. The Company’s lead development program, eRapa, is under development for familial adenomatous polyposis and non-muscle invasive bladder cancer; tolimidone, under development as a for the treatment of type 1 diabetes; and MTX110, which is being studied in aggressive rare/orphan brain cancer…
- Headquarters
- United Kingdom UK
- Employees
- 11
- IPO date
- Dec 8, 2014
Earnings Waterfall
Biodexa Pharmaceuticals PLC
The intrinsic value for Biodexa Pharmaceuticals PLC (BDRX) under the Base Case is 5.5666 USD.
Compared with the current market price of 0.4314 USD, the stock appears Undervalued by 92% .